Back to News
Market Impact: 0.2
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
Preclinical data suggest targeting PRC2 through EED may offer advantages over EZH2 inhibition. The EED inhibitor rinzimetostat maintained effectiveness against resistance mutations that can emerge with EZH2 inhibitors such as mevrometostat; the findings remain preclinical.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Trump Pushes DOJ Lawsuit Over Alaska Senate Race
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30